Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

The FDA granted traditional approval to pirtobrutinib (Jaypirca) for relapsed/refractory chronic lymphocytic leukemia/small ...

Roche is being called on to drop the price of its breast cancer drug Kadcyla in the UK so that patients can keep receiving the treatment. The drug is set to be 'de-listed' from England's Cancer Drugs ...

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive ...

After reviewing the positive findings in HER2-positive early-stage breast cancer from both DESTINY-Breast11 (DB-11) and ...

NICE has rejected Roche's breast cancer treatment Kadcyla for a second time, saying its benefits do not justify its price, even after a discount from the manufacturer. The decision has been called ...

EXCLUSIVE: Cancer patients, oncologists and advocates tell Rhian Lubin why the US health insurance system needs urgent reform, and is risking the lives of Americans fighting the disease ...

A campaign push by some Republicans to make contraceptive drugs available without a prescription has some support from medical groups despite objections from women's health advocates. New York City ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Defence Therapeutics ( (TSE:DTC)) has ...

Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.